Bosman I J, Avegaart S R, Lawant A L, Ensing K, de Zeeuw R A
Groningen Istitute for Drug Studies (GIDS), University Centre for Pharmacy, Department of Analytical Chemistry and Toxicology, The Netherlands.
J Pharm Biomed Anal. 1998 Jul;17(3):493-9. doi: 10.1016/s0731-7085(97)00238-0.
The objective of this study was to evaluate the performance of a new, compact, dynamic diffusion cell for in vitro transdermal permeation. These so-called Kelder-cells were developed as an automated alternative to the static Franz diffusion cells. The new cells were used in combination with the ASPEC-system (automatic sample preparation with extraction columns) which was initially designed for the automation of solid-phase extractions. Three variables were tested to optimize the performance of the new cell system: injection height into the inlet compartment, volume flowing through the receptor compartment and temperature. Experiments were performed using the tritium labelled anticholinergic [3H]dexetimide permeating through an artificial membrane (Silastic). The injection height of the needle into the inlet compartment of the cell should be programmed at -34 mm to ensure complete air tightness, thus forcing the buffer to flow through the cell. The volume of buffer flow through the receptor compartment is important in maintaining sink conditions: a volume of 117 microliters was chosen to replace the total content of the cell (84 microliters) every 2 min. The temperature was precisely controlled in a thermostatic cabinet to minimize variations in experimental conditions. For [3H]dexetimide, an increase in temperature of 20 degrees C reduced the lag time by a factor of approximately two, however the influence on the flux was negligible. The data for the Kelder-cells were comparable with static Franz diffusion cells at a pseudo-steady state, however Kelder-cells have the advantage of automatic sampling, continuous replacement of the receptor solution, and unattended operation over at least 24 h.
本研究的目的是评估一种新型紧凑型动态扩散池用于体外透皮渗透的性能。这些所谓的凯尔德扩散池是作为静态弗兰兹扩散池的自动化替代设备而开发的。新型扩散池与最初为固相萃取自动化设计的ASPEC系统(带萃取柱的自动样品制备系统)结合使用。测试了三个变量以优化新型扩散池系统的性能:注入进样隔室的高度、流经接收隔室的体积和温度。使用氚标记的抗胆碱能药物[³H]右苯丙胺透过人工膜(硅橡胶)进行实验。针注入扩散池进样隔室的高度应设定为-34毫米以确保完全气密,从而迫使缓冲液流经扩散池。流经接收隔室的缓冲液体积对于维持漏槽条件很重要:选择117微升的体积以每2分钟替换扩散池的全部内容物(84微升)。温度在恒温箱中精确控制以尽量减少实验条件的变化。对于[³H]右苯丙胺,温度升高20℃可使滞后时间缩短约两倍,然而对通量的影响可忽略不计。在伪稳态下,凯尔德扩散池的数据与静态弗兰兹扩散池的数据相当,但是凯尔德扩散池具有自动采样、连续更换接收溶液以及至少24小时无人值守操作的优点。